67 related articles for article (PubMed ID: 12181931)
1. [MS patients should get beta-interferon therapy early and for a long time].
Ruutiainen J
Duodecim; 2001; 117(17):1693-5. PubMed ID: 12181931
[No Abstract] [Full Text] [Related]
2. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
4. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Farrell RA; Giovannoni G
Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
[TBL] [Abstract][Full Text] [Related]
5. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
7. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
8. [The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia].
Medina-Redondo F; Herrera-Carranza J; Sanabria C; Navarro G; García-Moreno JM; Gamero-García MA; Páramo MD; Ruiz-Peña JL; Izquierdo G
Rev Neurol; 2004 Jul 1-15; 39(1):1-6. PubMed ID: 15257519
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
10. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
Clin Immunol; 2006 Jan; 118(1):77-82. PubMed ID: 16275091
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
12. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
[TBL] [Abstract][Full Text] [Related]
13. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
14. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
15. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
[No Abstract] [Full Text] [Related]
17. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
18. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Durelli L; Barbero P; Clerico M;
Neurology; 2006 Dec; 67(12):2264; author reply 2264-5. PubMed ID: 17190964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
